Статья
АКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИ ИСТИННАЯ РЕЗИСТЕНТНОСТЬ И ПСЕВДОРЕЗИСТЕНТНОСТЬ К АСПИРИНУ
Низкая доза аспирина уменьшает риск развития повторного инфаркта миокарда и инсульта. Резистентность к аспирину может снизить эффективность лечения, именно поэтому данный вопрос обращает на себя все большее внимание. Группа ученых из университета Пенсильвании (Филадельфия, США) во главе с доктором Tilo Grosser поставила цель определить генетически обусловленный механизм развития устойчивости к аспирину и выявить специфический фенотип истинной фармакологической резистентности к аспирину. Однако в ходе исследования не было выявлено ни одного случая истинной лекарственной резистентности. Псевдорезистентность была вызвана исключительно кишечнорастворимой оболочкой таблетки аспирина.
1. Martin C.P., Talbert R.L. Aspirin Resistance: An evaluation of Current Evidence and Measurement Methods. Pharmacotherapy 2005; 25(7):942–953.
2. Hankey G.J., Eikelboom J.W. Aspirin resistance. Lancet 2006;367(9510):606–17.
3. Topol E.J., Easton D., Harrington R.A., et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399–406.
4. Bhatt D.L., Chew D.P., Hirsch A.T., et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363–368.
5. Chen W.H., Lee P.Y., Ng W., et al. Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol 2005;45:382A.
6. Bhatt D.L., Topol E.J. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am 2000;84:163–179.
7. Hostetter J.C., Bhatt D.L. The expanding role of Antiplatelet agents in coronary artery disease. Miner- va Cardioangiol 2003; 51:531–46.
8. Cipollone F., Rocca B., Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004;24(2):246–55.
9. Cotter G., Shemesh E., Zehavi M., et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004;147(2):293–300.
10. Pulcinelli F.M., Pignatelli P., Celestini A., et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004;43(6):979–84.
11. Ray W.A., Stein C.M., Hall K., et al. Nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002;359:118–23.
12. Livio V., Delmaschio A., Cerletti C., deGaetano G. Indomethacin prevents long-lasting inhibitory effects of aspirin on human platelet cyclooxygenase. Prostaglandins 1982; 23:787–96.
13. MacDonald T.M., Wei L. Effect of ibuprofen on cardioprotecive effect of aspirin. Lancet 2003; 361:573–4.
14. Hurlen M., Seljeflot I., Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000;99(5):487–94.
15. Kawasaki T., Ozeki Y., Igawa T., Kambayashi J. Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591–5.
16. Grundmann K., Jaschonek K., Kleine B., et al. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250(1):63–6.
17. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78(3):1003– 7.
18. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natu- ral history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961–5.
19. Grosser T, Fries S, Lawson JA et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 2013;127(3):377–85.
20. Muir N., Nichols J.D., Clifford J.M., et al. The influence of dosage form on aspirin kinetics: implications for acute cardiovascular use. Curr Med Res Opin 1997;13:547–553.
21. Bochner F., Somogyi A.A., Wilson K.M. Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 1991;21:394–399.
22. Maree A.O., Curtin R.J., Dooley M., et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–1263.
23. Cox D., Maree A.O., Dooley M., et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:2153–2158.
24. Peace A., McCall M., Tedesco T., et al. The role of weight and enteric coating on aspirin response in cardiovascular patients. J Thromb Haemost 2010;8:2323–2325.
25. Reilly I.A., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180–186.
26. Patrono C., Ciabattoni G., Pinca E., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317–327.
27. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009;53:667–677.
28. Faraday N., Yanek L.R., Mathias R., et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007;115:2490–2496.
29. Webster S.E., Payne D.A., Jones C.I., et al. Anti-platelet effect of aspirin is substantially reduced after administration of heparin during carotid endarterectomy. J Vasc Surg 2004;40:463–468.
30. Valles J., Santos M.T., Aznar J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350–355.
31. Folts J.D., Schafer A.I., Loscalzo J., et al. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. J Am Coll Cardiol 1999;33:295–303.
32. Mehta S.R., Yusuf S., Peters R.J., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–533.
33. Schwartz K.A., Schwartz D.E., Ghosheh K., et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973– 975.
34. Hennekens C.H., Schneider W.R., Hebert P.R., et al. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to «aspirin resistance». Am Heart J 2010;159:744–748.
35. Pascale S., Petrucci G., Dragani A., et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603.
36. Rocca B., Santilli F., Pitocco D., et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220–1230.
37. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809–1817.
38. William H., John A. Collaborative overview of randomised trials of antiplatelet therapy: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet trialists’ collaboration. BMJ 1994;308:235–246. .